Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 18 Gastrointestinal 18 Thoracic 12 Head & Neck 7 Sarcoma 5 Breast 5 Tumor-Agnostic 4 Dermatologic 4 Genitourinary 3 CNS 3 Endocrine 2 Plasma cell 1 Lymphoid 1

Conditions

Multiple Myeloma 1

Interventions

Dexamethasone 262 Lenalidomide 157 daratumumab 135 Bortezomib 113 pomalidomide 89 Calcium Dobesilate 86 Cyclophosphamide 84 carfilzomib 76 Specimen Handling 46 isatuximab 44 fludarabine 43 Biopsy 43 belantamab mafodotin 41 Magnetic Resonance Spectroscopy 38 dexamethasone acetate 34 dexamethasone 21-phosphate 34 auricularum 33 Melphalan 32 talquetamab 29 ixazomib 27 iberdomide 27 fludarabine phosphate 24 selinexor 22 elotuzumab 21 Whole-Body Irradiation 17 X-Rays 15 venetoclax 14 Mycophenolic Acid 13 tocilizumab 12 Stem Cell Transplantation 11

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

dostarlimab × Plasma cell × 1 year × Clear all

NCT04126200 2026-05-06

DREAMM 5

GlaxoSmithKline

Phase 1/2 Active not recruiting

208 enrolled 5 charts

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡